Genetic analysis found cannabis use disorder can causally increase risk of developing other substance use disorders
Using Mendelian randomization and genomic analysis, researchers found that cannabis use disorder has causal genetic effects on opioid use disorder, problematic alcohol use, nicotine dependence, and smoking initiation, with bidirectional effects for most substances.
Quick Facts
What This Study Found
CUD showed significant causal effects on all analyzed substance use traits: opioid use disorder (IVW beta 0.925), problematic alcohol use (0.443), smoking initiation (0.405), drinks per week (0.182), nicotine dependence (0.183), and cigarettes per day (0.150). Bidirectional effects were found, with OUD, PAU, smoking initiation, and DPW also increasing CUD risk. Importantly, CUD and simple cannabis use loaded onto different genetic factors, indicating they are genetically distinct.
Key Numbers
CUD causal effect on OUD: IVW beta 0.925 (+/- 0.082). On problematic alcohol use: 0.443 (+/- 0.030). On smoking initiation: 0.405 (+/- 0.042). Bidirectional effects confirmed for OUD, PAU, smoking initiation, smoking cessation, and drinks per week.
How They Did This
Genetically informed analyses including local and global genetic correlations, genomic structural equation modeling (genomicSEM), and Mendelian Randomization (MR) using the latest CUD genomics data for unprecedented power.
Why This Research Matters
This is among the strongest evidence that the genetic predisposition to cannabis use disorder directly increases risk for other addictions. The finding that CUD and cannabis use are genetically distinct means that casual use and problematic use have different biological underpinnings.
The Bigger Picture
If CUD genetically increases risk for other addictions, cannabis legalization policies may need to account for downstream effects on opioid, alcohol, and tobacco use at the population level, beyond just cannabis-specific harms.
What This Study Doesn't Tell Us
Mendelian randomization assumes genetic instruments are valid; pleiotropy could confound results. European-ancestry-dominant samples limit generalizability. Genetic effects may interact with environmental factors not captured. Statistical causality does not perfectly map to clinical causality.
Questions This Raises
- ?Could early treatment of CUD prevent development of other substance use disorders?
- ?Are the shared genetic factors treatable targets?
Trust & Context
- Key Stat:
- CUD genetically increases opioid use disorder risk (beta 0.93)
- Evidence Grade:
- Advanced genomic methods (MR, genomicSEM) with unprecedented power provide strong genetic causal evidence, though genetic causality has caveats.
- Study Age:
- 2024 study
- Original Title:
- Genetic influences and causal pathways shared between cannabis use disorder and other substance use traits.
- Published In:
- Molecular psychiatry, 29(9), 2905-2910 (2024)
- Authors:
- Galimberti, Marco(2), Levey, Daniel F(3), Deak, Joseph D(2), Zhou, Hang, Stein, Murray B, Gelernter, Joel
- Database ID:
- RTHC-05320
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
What is Mendelian randomization?
A statistical method that uses genetic variants as natural experiments to estimate causal relationships. Because genes are assigned at conception, they are not affected by lifestyle factors, allowing researchers to separate cause from correlation.
Does this mean cannabis is a gateway drug?
The study shows shared genetic liability and causal genetic pathways between CUD and other substance disorders, which is more nuanced than the "gateway" concept. CUD (not just cannabis use) genetically increases risk, and the effects are bidirectional, with other substance disorders also increasing CUD risk.
Read More on RethinkTHC
- cannabis-cardiovascular-heart-risk-stroke
- cannabis-heart-cardiovascular-risk
- coughing-up-stuff-after-quitting-weed
- lung-recovery-after-quitting-smoking-weed
- lung-recovery-quitting-weed
- quitting-weed-female-hormones
- quitting-weed-weight-gain-loss-diet-appetite
- sex-after-quitting-weed
- weed-DUI-driving-impaired-cannabis-laws
- weed-acne-skin
- weed-fertility-sperm
- weed-gut-digestion-problems
- weed-heart-health
- weed-testosterone-levels
Cite This Study
https://rethinkthc.com/research/RTHC-05320APA
Galimberti, Marco; Levey, Daniel F; Deak, Joseph D; Zhou, Hang; Stein, Murray B; Gelernter, Joel. (2024). Genetic influences and causal pathways shared between cannabis use disorder and other substance use traits.. Molecular psychiatry, 29(9), 2905-2910. https://doi.org/10.1038/s41380-024-02548-y
MLA
Galimberti, Marco, et al. "Genetic influences and causal pathways shared between cannabis use disorder and other substance use traits.." Molecular psychiatry, 2024. https://doi.org/10.1038/s41380-024-02548-y
RethinkTHC
RethinkTHC Research Database. "Genetic influences and causal pathways shared between cannab..." RTHC-05320. Retrieved from https://rethinkthc.com/research/galimberti-2024-genetic-influences-and-causal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.